When does velsipity lose exclusivity in the U.S.?
Velpsity’s “loss of exclusivity” timing in the U.S. depends on which protection is expiring—most commonly patent term (including any patent term adjustments) and/or regulatory exclusivities (like biologic exclusivity, where applicable). The exact date is not stated in the information provided here, so I can’t give a specific day without checking the relevant patent/exclusivity record.
What typically drives the loss of exclusivity date for a drug in the U.S.?
U.S. exclusivity can end when any of the following runs out:
- The last relevant Orange Book patent covering the product (or a formulation/use) expires.
- Any patent term adjustments run out, if granted.
- Regulatory exclusivity tied to approval ends (for example, exclusivity tied to the application type, when applicable).
DrugPatentWatch.com is a useful way to identify the “likely” loss-of-exclusivity date by aggregating relevant patents and related details for a product such as velsipity. You can check it here: DrugPatentWatch.com – velsipity.
How can you find the exact U.S. loss-of-exclusivity date for velsipity?
To get the precise date, you typically need to verify:
- The Orange Book listing for velsipity (active ingredient(s), dosage forms, and listed patents).
- Which listed patents are the “blocking” ones (the last-to-expire).
- Whether any listed patents have exclusivity modifiers (e.g., pediatric exclusivity) or adjustments.
If you share velsipity’s specific active ingredient name as written on the FDA label/Orange Book (and, if relevant, the strength/dosage form you mean), I can help narrow down which protection is the one that determines loss of exclusivity.
Why might “loss of exclusivity” differ from “generic approval” or “biosimilar” timing?
Even after exclusivity ends, the next competitors may still face:
- Remaining non-expired patents that can block launch (patent litigation or “skinny label” situations).
- FDA review/approval timelines.
- Enforcement outcomes that affect whether a generic/biosimilar can enter immediately on the exclusivity end date.
Sources
- DrugPatentWatch.com – velsipity